| Literature DB >> 25043816 |
Michele Petruzzelli1, Martina Schweiger2, Renate Schreiber2, Ramon Campos-Olivas3, Maria Tsoli4, John Allen5, Michael Swarbrick5, Stefan Rose-John6, Mercedes Rincon7, Graham Robertson5, Rudolf Zechner2, Erwin F Wagner8.
Abstract
Cancer-associated cachexia (CAC) is a wasting syndrome characterized by systemic inflammation, body weight loss, atrophy of white adipose tissue (WAT) and skeletal muscle. Limited therapeutic options are available and the underlying mechanisms are poorly defined. Here we show that a phenotypic switch from WAT to brown fat, a phenomenon termed WAT browning, takes place in the initial stages of CAC, before skeletal muscle atrophy. WAT browning is associated with increased expression of uncoupling protein 1 (UCP1), which uncouples mitochondrial respiration toward thermogenesis instead of ATP synthesis, leading to increased lipid mobilization and energy expenditure in cachectic mice. Chronic inflammation and the cytokine interleukin-6 increase UCP1 expression in WAT, and treatments that reduce inflammation or β-adrenergic blockade reduce WAT browning and ameliorate the severity of cachexia. Importantly, UCP1 staining is observed in WAT from CAC patients. Thus, inhibition of WAT browning represents a promising approach to ameliorate cachexia in cancer patients.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25043816 DOI: 10.1016/j.cmet.2014.06.011
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287